241 related articles for article (PubMed ID: 36119068)
41. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
42. Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.
Xiao L; Li Q; Huang Y; Fan Z; Ma L; Liu B; Yuan X
J Healthc Eng; 2022; 2022():7651758. PubMed ID: 35251577
[TBL] [Abstract][Full Text] [Related]
43. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
44. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
46. A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Ou W; Wang SY
Front Immunol; 2023; 14():1147528. PubMed ID: 37033934
[TBL] [Abstract][Full Text] [Related]
47. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
48. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
[TBL] [Abstract][Full Text] [Related]
49. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
[TBL] [Abstract][Full Text] [Related]
50. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
51. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
52. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
54. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
55. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
56. PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes.
Feng B; Pan B; Huang J; Du Y; Wang X; Wu J; Ma R; Shen B; Huang G; Feng J
Cancer Lett; 2023 Jul; 565():216224. PubMed ID: 37196909
[TBL] [Abstract][Full Text] [Related]
57. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes.
Xiong Z; Zhang L; Fan W
J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579
[TBL] [Abstract][Full Text] [Related]
58. Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
Li J; Zhang H; Wu J; Li L; Xu B; Song Q
Cancer Biomark; 2023; 38(1):77-102. PubMed ID: 37545222
[TBL] [Abstract][Full Text] [Related]
59. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
[TBL] [Abstract][Full Text] [Related]
60. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
